Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$76.67 - $87.62 $70.7 Million - $80.8 Million
-922,100 Reduced 41.6%
1,294,300 $101 Million
Q2 2024

Aug 14, 2024

BUY
$66.81 - $80.83 $30.9 Million - $37.3 Million
461,800 Added 26.32%
2,216,400 $173 Million
Q1 2024

May 15, 2024

BUY
$61.03 - $69.57 $34.4 Million - $39.2 Million
563,100 Added 47.26%
1,754,600 $119 Million
Q4 2023

Feb 14, 2024

SELL
$61.89 - $69.28 $32.6 Million - $36.5 Million
-527,400 Reduced 30.68%
1,191,500 $80.2 Million
Q3 2023

Nov 14, 2023

BUY
$64.85 - $71.7 $62.7 Million - $69.3 Million
967,000 Added 128.61%
1,718,900 $116 Million
Q2 2023

Aug 14, 2023

BUY
$69.91 - $75.81 $14.7 Million - $15.9 Million
210,000 Added 38.75%
751,900 $53.8 Million
Q1 2023

May 15, 2023

SELL
$63.15 - $71.6 $13.3 Million - $15.1 Million
-210,432 Reduced 27.97%
541,900 $37.6 Million
Q4 2022

Feb 14, 2023

BUY
$54.21 - $70.44 $19.1 Million - $24.8 Million
351,736 Added 87.8%
752,332 $51 Million
Q3 2022

Nov 14, 2022

SELL
$53.02 - $135.75 $5.98 Million - $15.3 Million
-112,712 Reduced 21.96%
400,596 $22 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $203B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.